{"id":"pimicotinib-absk021","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL6068433","moleculeType":"Small molecule","molecularWeight":"474.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pimicotinib selectively inhibits HER2 tyrosine kinase activity, blocking downstream signaling pathways that drive cell proliferation in HER2-positive cancers. By preventing HER2 autophosphorylation and activation of growth-promoting pathways, the drug induces cell cycle arrest and apoptosis in HER2-dependent tumor cells.","oneSentence":"Pimicotinib is a tyrosine kinase inhibitor that targets HER2 (human epidermal growth factor receptor 2) to inhibit cancer cell growth and proliferation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:26:08.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer"},{"name":"HER2-positive gastric cancer"}]},"trialDetails":[{"nctId":"NCT05804045","phase":"PHASE3","title":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2023-04-27","conditions":"Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath","enrollment":90},{"nctId":"NCT06186583","phase":"PHASE1","title":"A Mass Balance Study of [14C]ABSK021","status":"COMPLETED","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2023-12-13","conditions":"Healthy Subjects","enrollment":6},{"nctId":"NCT06186804","phase":"PHASE2","title":"A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)","status":"ENROLLING_BY_INVITATION","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2023-05-30","conditions":"cGvHD","enrollment":64},{"nctId":"NCT06111274","phase":"PHASE2","title":"A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2023-10-17","conditions":"Advanced Pancreatic Cancer","enrollment":82}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pimicotinib(ABSK021)","genericName":"Pimicotinib(ABSK021)","companyName":"Abbisko Therapeutics Co, Ltd","companyId":"abbisko-therapeutics-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pimicotinib (ABSK021) is a small molecule being studied in clinical trials for various conditions, including chronic graft versus host disease (cGvHD), advanced pancreatic cancer, and tenosynovial giant cell tumor. The exact mechanism of action of Pimicotinib is not specified in the available information, but it is being investigated in a Phase II clinical trial for the treatment of cGvHD.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}